{"success":true,"data":{"pressRelease":{"id":"63506","rtpr_id":"nGNX4lkRyS","ticker":"LFCR","exchange":"NASDAQ","all_tickers":["LFCR"],"title":"Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company","author":"Globe Newswire","published_at":"2026-06-15T11:05:00.129Z","article_body":"--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently\nMarketed Neurology Product--\n\n--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--\n\nCHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.\n(NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract\ndevelopment and manufacturing organization (“CDMO”), today announced it\nhas signed a new agreement with a global pharmaceutical company. Under the\nterms of the agreement, Lifecore will perform technical transfer services to\nsupport the commercial production of an injectable suspension product for\nneurological disorders.   \n\n“With this significant new customer win, we have secured our seventh\nagreement for a late-stage program within the last seven months, reflecting\nhow our focused business development efforts have created strong momentum and\nresults for continued portfolio growth,” said Paul Josephs, chief executive\nofficer of Lifecore. “Being selected to produce this higher-viscosity\nsuspension formulation demonstrates confidence in Lifecore’s technical\nknow-how and exceptional quality track record.\n\n“This opportunity also highlights the increasing demand for specialized\nmanufacturing expertise to produce high-viscosity and other complex\npharmaceutical products. Lifecore’s unique capabilities position us as a\nvaluable partner, able to address the diverse needs of multinational\npharmaceutical companies seeking to leverage manufacturing operations in the\nU.S.”\n\nAbout Lifecore Biomedical\n\nLifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract\ndevelopment and manufacturing organization (CDMO) that offers highly\ndifferentiated capabilities in the development, fill and finish of sterile\ninjectable pharmaceutical products in syringes, vials, and cartridges,\nincluding complex formulations. As a leading manufacturer of premium,\ninjectable-grade hyaluronic acid, Lifecore brings more than 40 years of\nexpertise as a partner for global and emerging biopharmaceutical and\nbiotechnology companies across multiple therapeutic categories to bring their\ninnovations to market. For more information about the company, visit\nLifecore’s website at www.lifecore.com.\n\nImportant Cautions Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements regarding future events\nand our future results that are subject to the safe harbor created under the\nPrivate Securities Litigation Reform Act of 1995 and other safe harbors under\nthe Securities Act of 1933 and the Securities Exchange Act of 1934. Words such\nas “anticipate”, “estimate”, “expect”, “project”, “aim,”\n“designed to,” “plan”, “intend”, “believe”, “may”,\n“might”, “will”, “should”, “can have”, “likely” and\nsimilar expressions are used to identify forward-looking statements. In\naddition, all statements regarding our future financial and operating\nperformance and strategy, including our strong momentum and results for\ncontinued portfolio growth; the increasing demand for specialized\nmanufacturing expertise to produce high-viscosity and other complex\npharmaceutical products; and our position as a valuable partner, able to\naddress the diverse needs of multinational pharmaceutical companies seeking to\nleverage manufacturing operations in the U.S., are forward-looking statements.\nAll forward-looking statements involve certain risks and uncertainties that\ncould cause actual results to differ materially, including such factors as,\namong others, the timing and amount of future expenses, revenue, net income\n(loss), Adjusted EBITDA, cash flow and capital requirements, and timing and\navailability of and the need for additional financing; our ability to maintain\nor expand our relationships with our current customers, including the impact\nof changes in consumer demand for the products we manufacture for our\ncustomers; our ability to grow and diversify our business with new customers,\nincluding the potential loss of development customers if they do not receive\nrequired funding or regulatory approvals or for other reasons; our ability to\ncomply with covenants under our credit agreements and to pay required interest\nand principal payments when due; our ability to fund any redemptions of shares\nof the outstanding Series A Convertible Preferred Stock if requested by\nholders in accordance with their terms; our ability to raise additional\ncapital for ongoing needs, including through equity financing, debt financing,\ncollaborations, strategic alliances or licensing arrangements; the impact of\nmacroeconomic events or circumstances on our operations and financial\nperformance, including inflation, tariffs, interest rates, social unrest and\nglobal instability; the performance of our third-party suppliers;\npharmaceutical industry market forces that may impact our customers’ success\nand continued demand for the products we produce for those customers; our\nability to recruit or retain key scientific, technical, business development,\nand management personnel and our executive officers; our ability to comply\nwith stringent U.S. and foreign government regulation in the manufacture of\npharmaceutical products, including current Good Manufacturing Practice, or\ncGMP; the outcome and cost of existing and any new litigation or regulatory\nproceedings; and other risk factors set forth from time to time in the\ncompany’s filings with the Securities and Exchange Commission (the\n“SEC”), including, but not limited to, the Annual Report on Form 10-KT for\nthe transition period ended December 31, 2025 (the “December 2025 10-KT”).\nFor additional information about factors that could cause actual results to\ndiffer materially from those described in the forward-looking statements,\nplease refer to our filings with the SEC, including the risk factors contained\nin the December 2025 10-KT. Forward-looking statements represent\nmanagement’s current expectations as of the date hereof and are inherently\nuncertain. Except as required by law, we do not undertake any obligation to\nupdate forward-looking statements made by us to reflect subsequent events or\ncircumstances.\n\nContact Information:\nVida Strategic Partners\nStephanie Diaz (Investors)\n415-675-7401\nsdiaz@vidasp.com\n\nJennifer Arcure (Media)\n917-603-0681\njarcure@vidasp.com\n\nLifecore Biomedical\nRyan D. Lake (CFO)\n952-368-6244\nryan.lake@lifecore.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ca940278-cc18-4a3f-93b7-d8a034c998c9)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4lkRyS","title":"Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company","author":"Globe Newswire","ticker":"LFCR","created":"2026-06-15T11:05:00.129Z","tickers":["LFCR"],"exchange":"NASDAQ","article_body":"--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently\nMarketed Neurology Product--\n\n--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--\n\nCHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.\n(NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract\ndevelopment and manufacturing organization (“CDMO”), today announced it\nhas signed a new agreement with a global pharmaceutical company. Under the\nterms of the agreement, Lifecore will perform technical transfer services to\nsupport the commercial production of an injectable suspension product for\nneurological disorders.   \n\n“With this significant new customer win, we have secured our seventh\nagreement for a late-stage program within the last seven months, reflecting\nhow our focused business development efforts have created strong momentum and\nresults for continued portfolio growth,” said Paul Josephs, chief executive\nofficer of Lifecore. “Being selected to produce this higher-viscosity\nsuspension formulation demonstrates confidence in Lifecore’s technical\nknow-how and exceptional quality track record.\n\n“This opportunity also highlights the increasing demand for specialized\nmanufacturing expertise to produce high-viscosity and other complex\npharmaceutical products. Lifecore’s unique capabilities position us as a\nvaluable partner, able to address the diverse needs of multinational\npharmaceutical companies seeking to leverage manufacturing operations in the\nU.S.”\n\nAbout Lifecore Biomedical\n\nLifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract\ndevelopment and manufacturing organization (CDMO) that offers highly\ndifferentiated capabilities in the development, fill and finish of sterile\ninjectable pharmaceutical products in syringes, vials, and cartridges,\nincluding complex formulations. As a leading manufacturer of premium,\ninjectable-grade hyaluronic acid, Lifecore brings more than 40 years of\nexpertise as a partner for global and emerging biopharmaceutical and\nbiotechnology companies across multiple therapeutic categories to bring their\ninnovations to market. For more information about the company, visit\nLifecore’s website at www.lifecore.com.\n\nImportant Cautions Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements regarding future events\nand our future results that are subject to the safe harbor created under the\nPrivate Securities Litigation Reform Act of 1995 and other safe harbors under\nthe Securities Act of 1933 and the Securities Exchange Act of 1934. Words such\nas “anticipate”, “estimate”, “expect”, “project”, “aim,”\n“designed to,” “plan”, “intend”, “believe”, “may”,\n“might”, “will”, “should”, “can have”, “likely” and\nsimilar expressions are used to identify forward-looking statements. In\naddition, all statements regarding our future financial and operating\nperformance and strategy, including our strong momentum and results for\ncontinued portfolio growth; the increasing demand for specialized\nmanufacturing expertise to produce high-viscosity and other complex\npharmaceutical products; and our position as a valuable partner, able to\naddress the diverse needs of multinational pharmaceutical companies seeking to\nleverage manufacturing operations in the U.S., are forward-looking statements.\nAll forward-looking statements involve certain risks and uncertainties that\ncould cause actual results to differ materially, including such factors as,\namong others, the timing and amount of future expenses, revenue, net income\n(loss), Adjusted EBITDA, cash flow and capital requirements, and timing and\navailability of and the need for additional financing; our ability to maintain\nor expand our relationships with our current customers, including the impact\nof changes in consumer demand for the products we manufacture for our\ncustomers; our ability to grow and diversify our business with new customers,\nincluding the potential loss of development customers if they do not receive\nrequired funding or regulatory approvals or for other reasons; our ability to\ncomply with covenants under our credit agreements and to pay required interest\nand principal payments when due; our ability to fund any redemptions of shares\nof the outstanding Series A Convertible Preferred Stock if requested by\nholders in accordance with their terms; our ability to raise additional\ncapital for ongoing needs, including through equity financing, debt financing,\ncollaborations, strategic alliances or licensing arrangements; the impact of\nmacroeconomic events or circumstances on our operations and financial\nperformance, including inflation, tariffs, interest rates, social unrest and\nglobal instability; the performance of our third-party suppliers;\npharmaceutical industry market forces that may impact our customers’ success\nand continued demand for the products we produce for those customers; our\nability to recruit or retain key scientific, technical, business development,\nand management personnel and our executive officers; our ability to comply\nwith stringent U.S. and foreign government regulation in the manufacture of\npharmaceutical products, including current Good Manufacturing Practice, or\ncGMP; the outcome and cost of existing and any new litigation or regulatory\nproceedings; and other risk factors set forth from time to time in the\ncompany’s filings with the Securities and Exchange Commission (the\n“SEC”), including, but not limited to, the Annual Report on Form 10-KT for\nthe transition period ended December 31, 2025 (the “December 2025 10-KT”).\nFor additional information about factors that could cause actual results to\ndiffer materially from those described in the forward-looking statements,\nplease refer to our filings with the SEC, including the risk factors contained\nin the December 2025 10-KT. Forward-looking statements represent\nmanagement’s current expectations as of the date hereof and are inherently\nuncertain. Except as required by law, we do not undertake any obligation to\nupdate forward-looking statements made by us to reflect subsequent events or\ncircumstances.\n\nContact Information:\nVida Strategic Partners\nStephanie Diaz (Investors)\n415-675-7401\nsdiaz@vidasp.com\n\nJennifer Arcure (Media)\n917-603-0681\njarcure@vidasp.com\n\nLifecore Biomedical\nRyan D. Lake (CFO)\n952-368-6244\nryan.lake@lifecore.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ca940278-cc18-4a3f-93b7-d8a034c998c9)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-15T11:05:00.173957504Z","server_sent_at_ms":1781521500173},"received_at":"2026-06-15T11:05:00.332Z","source_url":null},"analysis":{"id":"52931","press_release_id":"63506","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":["Partner identity is undisclosed ('global pharmaceutical company'), limiting ability to assess deal quality or strategic fit","No financial terms or deal value disclosed"],"eventType":"partnership","narrative":"Lifecore Biomedical signed a new agreement with an unnamed global pharmaceutical company to perform technical transfer and commercial manufacturing for an injectable suspension product treating neurological disorders.\n\nThis marks the company's seventh late-stage program agreement in the last seven months, highlighting strong business development momentum and demand for its specialized high-viscosity manufacturing capabilities.\n\nCEO Paul Josephs stated the win demonstrates confidence in Lifecore's technical know-how and quality track record, positioning the firm as a valuable partner for multinational companies seeking U.S.-based manufacturing.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"LFCR adds 7th late-stage win in 7 months; new neurology manufacturing deal signals strong CDMO momentum."},"keyFigures":{"customDimensions":{"late_stage_wins_count":7,"late_stage_wins_period":"7 months"}},"quotedText":"With this significant new customer win, we have secured our seventh agreement for a late-stage program within the last seven months, reflecting how our focused business development efforts have created strong momentum and results for continued portfolio growth","namedEntities":{"people":[{"name":"Paul Josephs","role":"CEO"},{"name":"Ryan D. Lake","role":"CFO"},{"name":"Stephanie Diaz","role":"Investor Relations (Vida Strategic Partners)"},{"name":"Jennifer Arcure","role":"Media (Vida Strategic Partners)"}],"products":["injectable suspension product for neurological disorders","hyaluronic acid"],"companies":[{"name":"Lifecore Biomedical, Inc.","ticker":"LFCR","relationship":"filer"},{"name":"global pharmaceutical company","relationship":"partner"},{"name":"Vida Strategic Partners","relationship":"PR firm"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"A new commercial manufacturing agreement with a global pharma company validates Lifecore's specialized capabilities and adds to a strong pipeline of 7 late-stage wins in 7 months. While the specific partner and deal value are undisclosed, the momentum signal is positive for a mid-cap CDMO."},"tickerRelevance":{"others":[],"primary":"LFCR"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"contract_win","sectorWeight":"moderate","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Lifecore Biomedical signed a new agreement with an unnamed global pharmaceutical company to perform technical transfer and commercial manufacturing for an injectable suspension product treating neurological disorders.\n\nThis marks the company's seventh late-stage program agreement in the last seven months, highlighting strong business development momentum and demand for its specialized high-viscosity manufacturing capabilities.\n\nCEO Paul Josephs stated the win demonstrates confidence in Lifecore's technical know-how and quality track record, positioning the firm as a valuable partner for multinational companies seeking U.S.-based manufacturing.","key_figures":{"customDimensions":{"late_stage_wins_count":7,"late_stage_wins_period":"7 months"}},"named_entities":{"people":[{"name":"Paul Josephs","role":"CEO"},{"name":"Ryan D. Lake","role":"CFO"},{"name":"Stephanie Diaz","role":"Investor Relations (Vida Strategic Partners)"},{"name":"Jennifer Arcure","role":"Media (Vida Strategic Partners)"}],"products":["injectable suspension product for neurological disorders","hyaluronic acid"],"companies":[{"name":"Lifecore Biomedical, Inc.","ticker":"LFCR","relationship":"filer"},{"name":"global pharmaceutical company","relationship":"partner"},{"name":"Vida Strategic Partners","relationship":"PR firm"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-15T11:10:05.436Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"contract_win","sectorWeight":"moderate","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":31092,"modelName":"george-droid-qwen-72b"}}